New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 6, 2014
10:17 EDTDF, BJRI, PPHM, PHH, HPHigh option volume stocks: PHH BJRI HP PPHM DF
News For PHH;BJRI;HP;PPHM;DF From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 23, 2015
08:37 EDTHPBofA/Merrill U.S. oil & gas analysts to hold an analyst/industry conference call
Subscribe for More Information
January 20, 2015
07:24 EDTBJRIBJ's Restaurants upgraded at KeyBanc
As previously reported, KeyBanc upgraded BJ's Restaurant to Buy from Hold. The firm cites shares underperformance, top-line momentum, and improving returns for the upgrade. Price target is $52.
06:30 EDTBJRIBJ's Restaurants upgraded to Buy from Hold at KeyBanc
January 16, 2015
10:01 EDTBJRIOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:31 EDTPPHMPeregrine announces Ohase II clinical data of bavituximab with sorafenib
Peregrine Pharmaceuticals announced the presentation of clinical data related to the company's immuno-oncology development program and its lead investigational immunotherapy drug candidate bavituximab at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium. In this single-center, single-arm, open-label investigator-sponsored trial, 38 patients with advanced HCC received bavituximab weekly and sorafenib twice daily until disease progression or toxicity. Data show that the combination of bavituximab and sorafenib is associated with an improved time to progression of 6.7 months, a disease specific survival of 8.7 months, a disease control rate of 58% and a 4-month progression-free survival of 62%. Two patients achieved a partial response according to Response Evaluation Criteria In Solid Tumors. The secondary endpoint of median overall survival was 6.2 months. The combination of bavituximab and sorafenib was well-tolerated in patients with advanced HCC with no indications of autoimmune adverse events that have been seen with other checkpoint immunotherapies.
07:58 EDTBJRIBJ's Restaurants shares should be bought on any weakness, says Oppenheimer
Subscribe for More Information
06:45 EDTBJRIBJ's Restaurants downgraded to Hold from Buy at Wunderlich
Subscribe for More Information
January 15, 2015
18:28 EDTBJRIOn The Fly: After Hours Movers
Subscribe for More Information
16:07 EDTBJRIBJ's Restaurants reports preliminary Q4 revenue $213.9M, consensus $214.23M
Reports preliminary Q4 revenue $213.9M, consensus $214.23M. Comparable restaurant sales for Q4 increased approximately 1.2%, compared to a decrease of 2.7% in the year-ago quarter.
January 13, 2015
10:08 EDTPHHHigh option volume stocks
Subscribe for More Information
07:30 EDTPHHPHH Corp. shares poised to advance in 2015, says Oppenheimer
Subscribe for More Information
January 12, 2015
11:14 EDTPPHMDenver patient being tested for Ebola, KUSA-TV reports
A patient recently returned from Ebola affected areas in Africa is being tested in Denver for the disease, reported local NBC affiliate 9New KUSA-TV. Drug companies that are working on experimental Ebola vaccines or treatments include Peregrine (PPHM), Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX) and NewLink Genetics (NLNK). Some companies that offer protective clothing and waste disposal include Lakeland Industries (LAKE) and Alpha Pro Tech (APT). Reference Link
10:00 EDTDFOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:53 EDTDFDean Foods downgraded to Neutral from Outperform at Credit Suisse
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use